Abbonarsi

Combined immunodeficiency caused by a novel homozygous NFKB1 mutation - 04/02/21

Doi : 10.1016/j.jaci.2020.08.040 
Amarilla B. Mandola, MD a, b, c, d, Nigel Sharfe, PhD a, c, b, Zahra Nagdi, MSc a, c, b, Harjit Dadi, PhD a, c, b, Linda Vong, PhD a, b, c, Daniele Merico, PhD e, f, Bo Ngan, MD g, Brenda Reid, RN, MN a, b, Chaim M. Roifman, CM, MD a, b, c, d,
a Canadian Centre for Primary Immunodeficiency and the Jeffrey Modell Research Laboratory for the Diagnosis of Primary Immunodeficiency, Toronto, Ontario, Canada 
b Division of Immunology and Allergy, Department of Paediatrics, Hospital for Sick Children, Toronto, Ontario, Canada 
c Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada 
d Department of Immunology, University of Toronto, Toronto, Ontario, Canada 
e The Centre for Applied Genomics, Hospital for Sick Children, Toronto, Ontario, Canada 
f Deep Genomics Inc, Toronto, Ontario, Canada 
g Department of Laboratory Medicine and Pathobiology, Hospital for Sick Children, Toronto, Ontario, Canada 

Corresponding author: Chaim M. Roifman, CM, MD, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario M5G 1X8, Canada.The Hospital for Sick Children555 University AvenueTorontoOntarioM5G 1X8Canada

Abstract

Background

Genetic faults in several components of the nuclear factor-κB pathway cause immunodeficiency. Most defects lead to combined immunodeficiency with a range of severity. Heterozygous mutations in NFKB1 were associated with common variable immunodeficiency, however, homozygous mutations have not been described.

Objective

We studied the molecular basis of combined immunodeficiency in a patient who presented with failure to thrive, persistent EBV viremia and hepatitis, pneumocystis jirovecii pneumonitis, and generalized lymphadenopathy.

Methods

Whole genome and exome sequencing followed by Sanger confirmation were performed to identify the genetic defect. Molecular and cellular techniques were used to assess the variant impact on the nuclear factor-κB pathway and lymphocyte function.

Results

Genetic analysis revealed a novel homozygous mutation in NFKB1, c.2878G>A, p.Gly960Arg (G960R). This affected p105 phosphorylation and p50 formation on antigen and cytokine stimulation, as well as attenuating nuclear signal transmission. As a result, both T- and B-cell maturation and function were perturbed. The number of memory CD4+ T cells were reduced, while CD8+ T cells consisted predominately of expanded differentiated populations. The function of T cells were diminished as shown by reduced responses to mitogens as well as diminished cytokine secretion. B-cell maturation was also affected, with decreased IgD+CD27+ memory B cells while transitional B cells were increased, likely contributing to the reduced ability to produce specific antibodies.

Conclusion

Homozygous G960R mutation in NFKB1 leads to a severe clinical presentation of combined immunodeficiency. This was associated with blockade of nuclear factor-κB pathway signaling, resulting in aberrations in T- and B-cell maturation and function.

Il testo completo di questo articolo è disponibile in PDF.

Key words : NFKB1, common variable immunodeficiency, combined immunodeficiency, hypogammaglobulinemia, autoimmunity, B-cell repertoire

Abbreviations used : NF-κB, RelA


Mappa


 This work was supported by Immunodeficiency Canada’s Distinguished Professorship in Immunology (C.M.R.), the Program for Immunogenomics and the Canadian Centre for Primary Immunodeficiency (C.M.R.), and the Jeffrey Modell Foundation and Immunodeficiency Canada (C.M.R.).
 Disclosure of potential conflict of interest: D. Merico is a full-time employee of Deep Genomics and is entitled to a stock option. The rest of the authors declare that they have no relevant conflicts of interest.


© 2020  American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 147 - N° 2

P. 727 - Febbraio 2021 Ritorno al numero
Articolo precedente Articolo precedente
  • Efficacy and economics of targeted panel versus whole-exome sequencing in 878 patients with suspected primary immunodeficiency
  • Craig D. Platt, Fatima Zaman, Wayne Bainter, Kelsey Stafstrom, Abuarahman Almutairi, Margot Reigle, Sabrina Weeks, Raif S. Geha, Janet Chou, International Consortium for Immunodeficiencies
| Articolo seguente Articolo seguente
  • Improving the diagnostic efficiency of primary immunodeficiencies with targeted next-generation sequencing
  • Mathieu Fusaro, Jérémie Rosain, Virginie Grandin, Nathalie Lambert, Sylvain Hanein, Cécile Fourrage, Nicholas Renaud, Marine Gil, Samuel Chevalier, Wadih Abou Chahla, Brigitte Bader-Meunier, Vincent Barlogis, Stéphane Blanche, David Boutboul, Martin Castelle, Thibault Comont, Jean-Sébastien Diana, Claire Fieschi, Lionel Galicier, Olivier Hermine, Alain Lefèvre-Utile, Marion Malphettes, Etienne Merlin, Eric Oksenhendler, Marlène Pasquet, Felipe Suarez, Isabelle André, Vivien Béziat, Geneviève De Saint Basile, Jean-Pierre De Villartay, Sven Kracker, Chantal Lagresle-Peyrou, Sylvain Latour, Frédéric Rieux-Laucat, Nizar Mahlaoui, Christine Bole, Patrick Nitschke, Elisabeth Hulier-Ammar, Alain Fischer, Despina Moshous, Bénédicte Neven, Alexandre Alcais, Guillaume Vogt, Jacinta Bustamante, Capucine Picard

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.